The Augustine Therapeutics pipeline is based on two validated molecular targets with a strong rationale for drug discovery and robust intellectual property: HDAC6 and GABABR1a.

We currently have three programs in development: our lead project targeting peripherally restricted and selective HDAC6i for CMT and CIPN is advancing into in preclinical development; our second program focusing on brain penetrant and selective HDAC6i is advancing into lead optimization, and our third program targeting subtype-selective GABABR1A activators for CMT1 is currently at the discovery stage.

PNS: peripheral nervous system; CNS: central nervous system; CMT: Charcot-Marie-Tooth; CIPN: Chemotherapy-induced neuropathy; ALS: amyotrophic lateral sclerosis | soon production